Abstract

Acquired haemophilia is a rare , life threatening bleeding disorder characterised by the development of auto-antibodies to coagulation factor VIII. Diagnosis is based upon the clinical history of mucocutaneous haemorrhages combined with a selective prolongation of the APTT. The condition is associated with a wide range of conditions, such as autoimmune diseases , solid and haematological malignancies. Treatment involves controlling the bleeding manifestations and eliminating the inhibitor antibodies. Three cases from our recent practice are used to highlight the variable severity of this condition.
[download-attachments container="div" style="list" dipslay_icon="1" display_count="1" display__size="0"]

References

1. Hay CR, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133(6): 591–605.
2. Baggio LN, Green D. Acquired Haemophilia. Rev Clin Exp Haematol 2001; 5: 389–404.
3. Franchini M, Gandini G, Di Paolantonio T, et al. Acquired Haemophilia: A concise review. Am J Hematol 2005; 80: 55-63.
4. Schwartz RS, Gabriel DA, Aledort LM, et al. A prospective study of treatment of acquired (autoimmune) factor VIII with high dose intravenous gammaglobulin. Blood 1995;86 (2):797–804.
5. Cohen AJ, Kesler CM. Acquired inhibitors. Bailleres Clin Haematol 1996; 9: 331–354.
6. Hay CR. Acquired Haemophilia. Baileres Clin Haematol 1998; 11: 287–303.
7. Lottenberg R, Kentro TB, Kitchens CS. Acquired Haemophilia. A natural history of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077–1081.
8. Stasi R, Brunetti M, Stipa E, et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103(12): 4424–4428.
9. Hart HC et al. Transplant Proceedings 1998; 20: 323–328.
10. Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired haemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105: 2287–2293.
    11 Sultan Y, Kazatchkine MD, Nydehgger U, et al. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. Am J Med 1991; 91: 35–39.
11. Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor Viia, independent of tissue factor:implications for the therapeutic mechanism of high dose factor VIIa in haemophilia. Blood 1994; 83(12): 3828–3829.
12. Hay CR, Neginer C, Ludham CA. The treatment of bleeding in acquired haemophilia with -recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78(6): 1463–1467.
13. Lusher JM. Acquired inhibitors to factor VIII in non-hemophiliac patients. In Kessler C, ed. Acquired haemophilia (ed. 2nd) Princeton NJ. 1995